Excelsior Solutions October Update

November 17, 2017 § Leave a comment


November 17, 2018
Source: Excelsior Solutions

Novartis Gene Therapy Released Ahead of Schedule

Earlier than expected, U.S. Food and Drug Administration (FDA) approved Kymriah, a revolutionary cancer treatment developed by Novartis Pharmaceuticals Corporation (Novartis) in late August.  This treatment involves a patients T cells being extracted and reprogrammed outside their body to recognize and target leukemia cells that have the specific antigen CD19 on their surface, and then subsequently being re-infused into the patient’s body with a heightened ability to recognize and kill those cells, leaving normal cells alone.  The approval of Kymriah marks the first time gene therapy will be available in the United States.

Importantly, Kymriah will impact the medical benefit rather than the pharmacy benefit.  Excelsior Solutions has confirmed that a limited number of locations throughout the country will be able to administer this treatment, perhaps fewer than ten.  Each facility and physician approved to administer this treatment will have completed an enhanced training course designed by the manufacturer, so patients will not be walking into their local pharmacy, or even using a specialty pharmacy, to have traditional “prescriptions” of Kymriah filled.

Initially, the use of Kymriah will not be widespread.  The disease for which Kymriah was developed (B-cell acute lymphoblastic leukemia that has resisted treatment or relapsed in children and young adults ages 3 to 25) is not common.  Only 5,000 people a year are affected, of whom 60 percent are children or young adults.

Because this is a customized treatment that involves modifying the patients T cells, a specialized single administration method, and aggressive monitoring for side effects, Kymriah will cost a on-time fee of $475,000.  However, Novartis revealed that through collaboration with the U.S. centers for Medicare and Medicaid Services, there will be no charge if a patient does not respond to Kymriah within the first month after the treatment.

Kymriah’s approval moves the ball forward in terms of biological treatments for this particular form of leukemia and opens the door for future individualized treatment development.

To learn more about the specifics of the Kymriah treatment, read the FDA’s press release announcing its approval and a technical explanation from the National Cancer Institute.

To see what others are saying about Novartis and Kymriah, visit FirstWord Pharma and The New York Times for related articles.

For more information on the management of specialty drug costs, please contact your Group Resources Account Manager.

Andy Willoughby
Senior Vice President & Chief Operating Officer
678 475 3606 – andy@groupresources.com

This electronic transmission and any attached document and/or file is confidential and intended for the use of the individuals to whom it is addressed. This communication may contain material protected by privacy Laws or regulations. Any further distribution or copying of this transmission and/or attached document or file is strictly prohibited. If you received this message in error, please notify the sender and destroy the message and all attached documents and/or files immediately. Group Resources is not liable for any use or misuse contrary to these directions.

For Healthier Employees and Healthier Businesses

Deception Behind In-Network Health Discounts

November 10, 2017 § Leave a comment


November 10, 2017

ObamaCare’s medical loss ration creates incentives for insurers and providers to hoodwink customers.
By Keith Lemer, CEO of The WellNet Healthcare Plan, a health-care services company.

discounts-basket

Here’s a strange paradox: Health-care costs have increased by an unsustainable rate of about 8.5% each year over the past decade, according to PwC’s Health Research Institute.  Already, the average employer-based family health insurance plans costs more than $18,000 annually.

But Medicare spending has been relatively stable.  Over the past three years, the program’s payouts to hospitals have increased by only 1% to 3% a year, roughly even with inflation.  The prices paid for some core services such as ambulance transportation, have actually gone down.

To see what’s happening, we can start by pulling back the curtain on how preferred provider organizations do business.  A PPO is a network of preferred health-care providers such as doctors and hospitals, typically assembled by an insurance carrier.  In theory, the insurer can save money for its customers by persuading providers in the network to discount their services in exchange for driving volume to their facilities.

United Healthcare Choice Plus, for instance, boasts that its PPO – a network of more than 780,000 professionals – cuts the cost of typical doctor visits by 52%, while saving 69% on MRIs.  Pull back the curtain, and you’ll see these discounts are an accounting trick.  To allow PPOs to advertise big discounts, providers simply inflate their billed charges on a whole range of services and treatments.

Don’t insurers have a natural incentive to keep provider prices down, even if they don’t end up paying the list price?

In fact, no-at least not since the Affordable Care Act took effect.  That law established a “medical loss ratio”, which requires insurers covering individuals and small businesses to spend at least 80 cents to every premium dollar on medical expenses.  Only 20 cents can go toward administrative costs and profit. (For insurers offering large group plans, the MLR rises to 85%.)

If a provider raises the cost of a blood test or medical procedure, insurers can charge higher premiums, while also boosting the value of their 20% share.  Insurers can make money only if they lower their administrative expenses or charge higher premiums.

In this way, the MLR rule encourages insurers to ignore providers’ artificial price hikes.  Insurers can continue to attract customers with the promise of steep discounts through their PPO plans – and providers can continue to ratchet up their prices.  By hoodwinking their customers, both insurers and providers make more money.  Since insurance costs are merely a derivative of health-care costs, the result has been a steady rise in insurance costs for millions of working families.

For employers caught in this price spiral, there is a way out: partial or full self-insurance.  When businesses self-insure, they pay employee health claims directly.  That creates an incentive for businesses to question – and push back on – providers’ price increases.  Self-insuring businesses can strengthen their leverage by using “reference-based pricing,” which caps payments for “shoppable” – nonemergency – services at the average price in a local market.  Members whose providers with prices below the limit receive full coverage.  If they use a provider that charges more than the limit, they pay the difference out-of-pocket.

This setup creates a strong incentive to control costs: Patients have a reason to shop around for the best value, while providers are pressured to keep their prices below the cap.  The most expensive doctor is not always the doctor with the best outcomes.

That’s what happened when the California Public Employee’s Retirement System adopted a reference-pricing approach a few years ago.  The agency had noticed that provider charges for hip and knee replacements varied from $15,000 to $110,000.  In 2010, Calpers established a reference price of $30,000 for the procedures. Predictably, patients flocked to providers charging that price or less and shunned higher-cost facilities.  Over the next couple of years, the number of California hospitals charging below $30,000 for a hip replacement jumped by more than 50%.  In the first year Calpers saved as estimated $2.8 million on joint replacements.

What worked for Calpers can work just as effectively for small and midsize businesses.  Today’s medical inflation is exactly what one would expect from health policies that reward insurers and providers for raising prices.  Employers should not accept this status quo.  By self-insuring and setting their own reference-based reimbursement, businesses can sidestep the traditional insurance model that continues to bleed them dry.

Mr. Lemer is CEO of The WellNet Healthcare Plan, a health-care services company.
Source: Riskmanagers.us

Andy Willoughby

Senior Vice President & Chief Operating Officer
(678) 475 3606 – andy@groupresources.com

This electronic transmission and any attached document and/or file is confidential and intended for the use of the individuals to whom it is addressed. This communication may contain material protected by privacy Laws or regulations. Any further distribution or copying of this transmission and/or attached document or file is strictly prohibited. If you received this message in error, please notify the sender and destroy the message and all attached documents and/or files immediately. Group Resources is not liable for any use or misuse contrary to these directions.

For Healthier Employees and Healthier Businesses

 

Adjusted Dollar Amounts for PCORI

November 6, 2017 § Leave a comment

November 3, 2017
SBPA Update: October 2017

Background
The Affordable Care Act imposes a fee on plan sponsors of certain self-funded health plans to help fund the Patient-Centered Outcomes Research Institute, as well as on fully insured carriers.  The fee, required to be reported once a year on the second quarter Form 720 and paid by its due date, July 31, is based on the average number of lives covered under the plan or policy.

The fee applies to plan or policy years ending on or after October 1, 2012 and before October 1, 2019.  The PCORI fee is filed using Form 720, Quarterly Federal Excise Tax Return.  Although Form 720 is a quarterly return, for purposes of PCORI, Form 720 is filed only once annually, July 31.

IRS Notice 2017-61
For policy years and plan years that end on or after October 1, 2017, and before October 1, 2018, IRS Notice 2017-61 provides the adjusted applicable dollar amounts to be multiplied by the average number of covered lives.

The below link provides a chart of the fees.
https://www.irs.gov/affordable-care-act/patient-centered-outreach-research-institute-filing-due-dates-and-applicable-rates

Calculating the Average Number of Lives
For self-funded plans, the fee imposed on a plan sponsor is based on the average number of lives (participants and dependents) covered under the plan.  The fee is calculated by multiplying the average number of lives covered under the plan for the plan year by the applicable dollar amount.  The final regulations offer a choice of three alternative methods to determine the average number of lives covered under a self-funded plan.  A plan sponsor must use the same method of calculating the average number of lives covered under the plan consistently for the duration of the year.

Three Alternative Methods

  • Actual Count Method – A plan sponsor may determine the average number of lives covered under the plan for the plan year by calculating the sum of the lives covered each day of the plan year and dividing that sum by the number of days in the plan year.
  • Snapshot Method – A plan sponsor may determine the average number of lives covered under the plan for the plan year by adding the total of lives covered on one date in each quarter (or an equal number of dates for each quarter) and dividing the total by the number of dates on which a count was made.  For those plans that do not track the number of dependents, a “snapshot factor method” is available. Under the “snapshot factor method,” the number of lives covered on a date is equal to the sum of the number of participants with self-only coverage on that date, plus the product of the number of participants with coverage other than self-only coverage on the date and 2.35.
    • Note: The Treasury Department and IRS developed the 2.35 dependency factor in consultation with economists and plan sponsors.
    • Please see the final regulation for examples demonstrating how to run the calculations.  §46.4376-1(c).  These examples are very helpful.
  • Form 5500 Method – The final rule sets forth a method to determine the average number of lives using the information from the Form 5500, with adjustments for dependents.  A plan sponsor may determine the average number of lives covered under a plan for a plan year based on the number of participants reported on the Form 5500, provided that the Form 5500 is filed no later than the due date for the PCORI fee.  The average number of lives covered under the plan for the plan year for a plan offering only self-only coverage equals the sum of the total participants covered at the beginning and the end of the plan year, as reported of the Form 5500, divided by two.  The average number of lives for a plan offering self-only coverage as well as family coverage equals the sum of the total participants covered at the beginning and at the end of the plan year.

 

For fully-insured plans, see the final regulations for the methods to determine average number of lives.
If an employer provides COBRA coverage or otherwise provides coverage to its retirees or other former employees, do covered individuals (and their beneficiaries) count as “lives covered” for purposes of calculating the PCORI fee?
Yes. 
These covered individuals and their beneficiaries must be taken into account in calculating the average number of lives covered.  Note: This Q&A was taken from the IRS webpage on PCORI.

 

Andy Willoughby

Senior Vice President & Chief Operating Officer
678 475 3606 – andy@groupresources.com

This electronic transmission and any attached document and/or file is confidential and intended for the use of the individuals to whom it is addressed. This communication may contain material protected by privacy Laws or regulations. Any further distribution or copying of this transmission and/or attached document or file is strictly prohibited. If you received this message in error, please notify the sender and destroy the message and all attached documents and/or files immediately. Group Resources is not liable for any use or misuse contrary to these directions.

For Healthier Employees and Healthier Businesses

Excelsior Solutions: Pharmacy News to Know August 2017

September 15, 2017 § Leave a comment


September 15, 2017

Source: Excelsior Solutions

FDA Approves AbbVie’s Mavyret for Hepatitis C
On August 3, 2017, the U.S. Food and Drug Administration approved AbbVie’s Mavyret to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6.  Mavyret is the first treatment of eight weeks duration that has been approved in adult patients without cirrhosis and who have not been previously treated.  Standard treatment length was previously 12 weeks or more.  The average wholesale price for some common hepatitis C medications are below:
Mavyret:  $15,840.00 per 28 day suppluy
Sovaldi:  (Mavyret ~56% less per 28-day supply)
Harvoni:  (Mavyret ~58% less per 28-day supply)
Epclusa:  (Mavyret ~47% less per 28-day supply)
Zepatier:  (Mavyret ~27% less per 28-day supply)

PBM’s and carriers are expected to finalize their formulary decision in September and we will be looking for them to favorable position Mavyret within their formularies.  Some PBM’s and carrier may choose not to position Mavyret favorably, and in those situations it will likely be because of improved rebates on the Gilead products (Sovaldi, Harvoni, Epclusa), making them lower net cost. In any event, Mavyret introduces additional competition into the market which will help drive down cost.

The Excelsior Solutions team will continue to monitor and keep you abreast as these formulary changes surrounding Hepatitis C medications are announced.
Trump Signs FDA Funding Bill
President Donald Trump recently signed into law the FDA Reauthorization Act of 2017.  This act reauthorizes a program in which drug and device makers pay a fee to the FDA for every new product application.  The agency uses that money to hire more people and speed up approvals.  The law also includes a measure that lets FDA hasten development of a generic drug in an off-patent product with no competition is being sold at an egregiously high price.  The user fee program must be reauthorized every 5 years, and the current program expires at the end of September.  The Trump administration had sought to have 100% of FDA be funded by user fees.  However, the user fee agreement had already been negotiated between the agency and the industry, leaving little time to return to the negotiating table.  What does this mean to plan sponsors?  Because we will see quicker approvals of generic alternatives, pharmaceutical manufacturers will have less opportunity to set egregiously high prices on off-patent drugs.
National Opioid Epidemic
August 2017 proved to be busy for the White House.  President Trump declared the opioid epidemic a national emergency in a move intended to direct more funding and attention toward the crisis.  According to a series of government briefs published this year, nearly 1.3 million hospitalizations involving opioids occurred in the United States in 2014.  The numbers reflect a 64 percent increase in inpatient stays and continue to double in emergency room visits related to opioids since 2005.  Between 2005 and 2014, inpatient stays involving opioids increased more sharply for women than men.  By 2014, women had higher rates of opioid-related inpatient stays in most states, though men typically had higher rates of emergency room treatment.  In the same decade, the national rate of opioid-related hospitalizations great most sharply among patients aged 25 to 44.  In much of the Midwest and West, however, rate of inpatient treatment were highest among patients 65 years and older.  PBM’s are beefing up their opioid and narcotic programs by offering enhanced buy-up programs to plan sponsors.  Strategies include the following CDC guidelines, implementing prior authorizations and quantity limits, locking “pharmacy shoppers” into one pharmacy, and sending letters to prescribers.

For more information on the management of specialty drug costs, please contact your account manager.
Andy Willoughby
Senior Vice President & Chief Operating Officer
678 475 3606 – andy@groupresources.com

This electronic transmission and any attached document and/or file is confidential and intended for the use of the individuals to whom it is addressed. This communication may contain material protected by privacy Laws or regulations. Any further distribution or copying of this transmission and/or attached document or file is strictly prohibited. If you received this message in error, please notify the sender and destroy the message and all attached documents and/or files immediately. Group Resources is not liable for any use or misuse contrary to these directions.

For Healthier Employees and Healthier Businesses

More Smaller Companies Are Self-Insuring Health Benefits

September 5, 2017 § Leave a comment


September 1, 2017

More Smaller Companies Are Self-Insuring Health Benefits
Source: MyHealthGuide, Sara Hansard (Health Care on Bloomberg Law)

 

Small and mid-sized companies are increasingly providing their own health coverage for employees instead of buying fully insured plans since Obamacare was enacted in 2010.

Workers in Self-Insured Plans Rising

Between 2013 and 2015, as a result of an increase in self-insured plans among small and mid-sized employers, the percentage of covered workers enrolled in self-insured plans increased from 58.2 percent to 60 percent, according to data from about 40,000 employers interviewed by the U.S. Department of Health and Human Services and compiled by the Employee Benefit Research Institute (EBRI).

Key Facts
The largest increases in self-insured coverage occurred in establishments with 100-999 employees, rising 21 percent from 33.6 percent of employees in 2013 to 40.5 percent in 2015, and among establishments with 25-99 employees, where the practice increased from 13.2 percent to 15.2 percent, a 15 percent increase.

Mercer Health & Benefits LLC, which provides health-care consulting and brokerage services, has also found increases in the use of self-funding among the employers it surveys annually, principal James Bernstein told Bloomberg BNA. Bernstein is based in Mercer’s Cincinnati office.

  • The largest movement Mercer found was among midsize companies with 500 to 1,000 employees.
  •  51% of those companies self-insured in 2014, while 66% did so in 2016.
  • Employers in the Midwest led the pack with about 74 percent self-insuring, while fewer employers in the Northeast and West Coast self-insured because health maintenance organizations such as Kaiser Permanente are more prevalent there.

If you have any questions, please do not hesitate to contact me or your Group Resources Account Manager.

Andy Willoughby
Senior Vice President & Chief Operating Officer
678 475 3606 – andy@groupresources.com

This electronic transmission and any attached document and/or file is confidential and intended for the use of the individuals to whom it is addressed. This communication may contain material protected by privacy Laws or regulations. Any further distribution or copying of this transmission and/or attached document or file is strictly prohibited. If you received this message in error, please notify the sender and destroy the message and all attached documents and/or files immediately. Group Resources is not liable for any use or misuse contrary to these directions.

For Healthier Employees and Healthier Businesses

Are you aware that Group Resources offers FSA administration services ?

August 21, 2017 § Leave a comment

August 18, 2017

A Flexible Spending Account (FSA) plan is a benefit provided by an employer under which an employee sets aside a certain amount of their paycheck into a medical flexible spending account before paying income taxes.  Then, during the year, they can be directly reimbursed from this account for qualified healthcare, or pay for eligible expenses at the time they are incurred, using the optional TakeCare flex debit card.  The money may be used for common out-of-pocket expenses (deductibles, co-pays for prescriptions or office visits, amounts over dental limits, annual physicals, eye exams, eye surgery, glasses, orthodontics, etc.) that qualify for payment with flex benefit dollars.  The money is ready and waiting whenever it is needed – it’s that simple.

By taking advantage of this flexible benefits plan, the employee is able to hold on to more of their paycheck in a special, easily accessible account.  Once enrolled, the entire amount estimated for healthcare expenses for the year will be available on the first day of the health plan year.  Any contributions that are not used during the plan year may not be paid to the employee in cash, however, the plan may offer a carryover provision.

FSAs can also be established for dependent day care, parking, transit and adoption expenses.  With these optional accounts:

  • A working parent can use their take care plan to cover the eligible expenses of child care;
  • Employees can realize significant savings on adult and elderly care expenses for a qualified member of the family; and
  • Transit or parking costs related to work may also be compensated under a take care flexible benefits plan.

It is simple for a participant to keep track of how much money is in their account through accessing www.myflexonline.com, or with the My Flex Mobile app (available in the Apple store and on Google Play).

The biggest advantage is the tax savings.  Every dollar set aside in an account reduces how much the participant pays later in income taxes.  Plus, it is possible to be reimbursed for qualified expenses that the participant may already be paying for.

For more information on the advantages of participating in a Flexible Spending Account plan, please contact me or your account manager.

 

Andy Willoughby
Senior Vice President & Chief Operating Officer
678 475 3606 – andy@groupresources.com

This electronic transmission and any attached document and/or file is confidential and intended for the use of the individuals to whom it is addressed. This communication may contain material protected by privacy Laws or regulations. Any further distribution or copying of this transmission and/or attached document or file is strictly prohibited. If you received this message in error, please notify the sender and destroy the message and all attached documents and/or files immediately. Group Resources is not liable for any use or misuse contrary to these directions.

For Healthier Employees and Healthier Businesses

 

Pharmacy News to Know

August 11, 2017 § Leave a comment

group logo.no inc
August 11, 2017

Pharmacy News to Know
From: Excelsior Solutions

Novartis New Gene Therapy Approval

Recently, the Food and Drug Administration recommended the approval of a new revolutionary cancer therapy developed by Novartis known as CAR-T.  CAR-T involves patients’ T cells being extracted and reprogrammed outside of their body to recognize and hunt cancer cells.  CAR-T is used in children and young adults ages 3 to 25 who have hard-to-treat forms of rare blood cancer B-cell acute lymphoblastic leukemia.  This rare disease affects roughly 5,000 people a year; about 60% of those patients are children and young adults.  Individualized treatments are predicted to cost more than $300k.  Because of the individualized nature of this treatment, preparation method, and the administration method, it remains undetermined if it will flow through the pharmacy benefit or the medical benefit.  The Excelsior Solutions team will continue monitoring the developments of this new treatment and the potential impact it could have on your plan spend.

Source: Novartis CAR-T cell therapy

Prostate Cancer Pipeline

Zytiga, the currently approved treatment used for men with metastatic, castration-resistant prostate cancer (mCRPC), may soon become a first-line treatment for high-risk patients, greatly expanding its potential market.  Approximately 119.8 per 100,000 men are diagnosed with prostate cancer each year.  There will be an estimated 161,360 new cases in 2017, and 60% of those cases are men 65 year of age or older.  Zytiga is estimated to cost $60k per year.  Currently, the leading two blockbusters for Prostate Cancer Drugs are Zytiga manufactured by Johnson & Johnson, and Xtandi manufactured by Astellas.  The Excelsior Solutions team will continue to watch the Prostate Cancer drugs pipeline for new developments.

Source: Zytiga extends prostate cancer survival

New Sickle Cell Disease Treatment

The FDA has approved a new orphan drug Endari (L-glutamine) for Sickle Cell disease.  Endari is used in patients age 5 years and older to reduce severe complications – it does not cure the disease.  Endari is the first treatment approved for Sickle Cell disease in almost 20 years.  The Sickle Cell disease is an inherited blood disorder in which the red blood cells are abnormally shaped.  These abnormal cells restrict the flow in blood vessels and limit oxygen delivery to the body’s tissues leading to severe pain and organ damage.  According to the National Institutes of Health, an estimated 100,000 people in the U.S. have Sickle Cell disease and about 275,000 babies are born with in each year worldwide.  The manufacturer of Endari is Emmaus Life Sciences Inc., and the price of treatment is unknown a the time.

Source: FDA approves new treatment for Sickle Cell disease

Plaque Psoriasis Pipeline

The FDA has recently approved Tremfya (guselkumab) for use in adults with moderate to severe plaque psoriasis.  Presently, Tremfya is the first and only approved psoriasis treatment that targets the inflammatory protein that plays a key role in plaque psoriasis.  Other alternative therapies, such as methotrexate, acitretin, and clyclosporine, have been available for decades and are less expensive treatments.  The manufacturer of Tremfya is Janssen, and the annual cost is estimated to be $58k.  Janssen has already announced that its patient support program is to include a copay card which will reduce out-of-pocket costs to as low as $5.

Source: Tremfya gets FDA approval for Plaque Psoriasis

 

For more information on the management of specialty drug costs, please contact your account manager.

 

Andy Willoughby
Senior Vice President & Chief Operating Officer
678 475 3606 – andy@groupresources.com

This electronic transmission and any attached document and/or file is confidential and intended for the use of the individuals to whom it is addressed. This communication may contain material protected by privacy Laws or regulations. Any further distribution or copying of this transmission and/or attached document or file is strictly prohibited. If you received this message in error, please notify the sender and destroy the message and all attached documents and/or files immediately. Group Resources is not liable for any use or misuse contrary to these directions.

For Healthier Employees and Healthier Businesses

State-mandated Continuation of Coverage and ERISA Preemption: What Self-funded Employers Need to Know

August 4, 2017 § Leave a comment

group logo.no inc

August 4, 2017

One subject that we often hear addressed is the pre-emption of state insurance law by the Employee Retirement Security Act of 1974 (“ERISA”).  We’ve recently come across two articles, that we have re-capped below, to shed some light on this matter:

What is ERISA & why was it enacted?

Congress enacted ERISA primarily to establish uniform federal standards to protect private employee pension plans from fraud and mismanagement.  ERISA applies to all employee pension, health and other benefits plans established by private sector employers (other than churches) or by employee organizations such as unions.  If they meet certain requirements employee plans are “ERISA plans” even if they offer benefits through state-licensed insurers.

Plans that ERISA regulates:

For health plans, federal law prescribes certain substantive standards: administrators’ fiduciary standards (to administer the plan in the best interests of beneficiaries), requirements for plan descriptions to be given to enrollees, reporting to the federal government, and certain minimum standards (“continuation” health coverage; group plan guaranteed issue and renewability; pre-existing condition exclusion requirements; nondiscrimination in premiums and eligibility; maternity hospital length-of-stay standards; post mastectomy reconstructive surgery; and limited mental health “parity”).

Who enforces and interprets ERISA?

The U.S Department of Labor is responsible for administering and enforcing the ERISA law and setting policy for the conduct of employee benefit plans.  The federal courts are the primary source of interpretations of ERISA’s preemption provisions.  Much of the uncertainty about whether ERISA affects a proposed state health care initiative or policy results from differing court interpretations of the preemption provisions across the country.

What self-funded employers need to know:

According to one prominent health law attorney, “Although in its text ‘hospital’ appears only once and ‘physician’ not all, ERISA may be the most important law [prior to the Affordable Care Act] affecting health care in the United States”.  William Sage, “Health Law 2000”: The Legal System and the Changing Health Care Market, 15(3) Health Aff. 9 (Aug. 1996).  Understanding the intricacies of ERISA and its preemption clause can be a challenge for even the most careful attorney.  Courts have held that ERISA supersedes some state health care initiatives, such as employer insurance mandates and some types of managed care plan standards, if they have a substantial impact on employer-sponsored health plans.  The Supreme Court has interpreted the preemption clause very broadly to carry out the congressional objective of national uniformity in rules for employee benefits programs.   The Court has held that ERISA preempts state laws that either refer explicitly to ERISA plans (i.e., all plans offered by private-sector employers) or have a substantial financial or administrative impact on them.  U.S. Supreme Court opinions limit ERISA’s impact on state authority, but many uncertain areas remain.

ERISA’s preemption provisions contain an exception important to state health policy that allows states to continue to regulate “the business of insurance” (authority that Congress gave to the states in McCarran-Ferguson Act of 1945).  Courts have interpreted ERISA’s insurance regulation “saving clause” to allow states to regulate traditional insurance carriers conducting traditional insurance business.  That clause is then qualified by the “deemer clause,” which acts as a kind of escape hatch through the savings clause.  For employers, that escape hatch is key because it allows them to avoid state insurance regulations by self-funding their health plans rather than by purchasing health insurance.

Under the insurance regulation saving clause, states can regulate terms and conditions of health insurance, for example, the benefits in an insurance policy or the rules under which a health insurance market must operate.  But through its so-called “deemer clause,” the statute prohibits states from regulating plans that “self-insure” by bearing the primary insurance risk, even though by bearing risk they appear to be acting like insurance companies.  According to the Society of Professional Benefit Administrators, approximately 75-80% of employees and their dependents receive benefits through self-insured group health plans sponsored by their employers.

Increasingly, however, states are testing the limits of preemption. Recent examples include, leave laws which mandate that employers continue health insurance coverage for eligible employees out on leave. Perhaps the best known leave law is the Federal Family and Medical Leave Act of 1993 (“FMLA”).  The statute, like most other Federal laws applies regardless of the source of insurance.  It requires employers to provide twelve weeks of unpaid, job-protected leave for an employee’s own serious health condition, for the birth or adoption of a child, or to care for a spouse, parent or child with an illness.

When determining whether preemption under ERISA is applicable, the key question to answer is whether the state law at issue  “relates to” an ERISA plan.  The U.S. Supreme Court has said that a state law “relates to” an employee benefit plan covered by ERISA if it refers to or has a connection with that plan, even if the law is not designed to affect the plan or the effect is only indirect.  See e.g., Ingersoll-Rand Co. v. McClendon, 498 U.S. 133, 139 (1990).

 

If you have any questions, please do not hesitate to contact me or your Group Resources Account Manager.

If you’d like to review the original articles, please follow the links below:

  1. http://www.nashp.org/erisa-preemption-primer/
  2. https://issuu.com/sipconlinepub/docs/self-insurer_aug_2017

 

Andy Willoughby
Senior Vice President & Chief Operating Officer
678 475 3606 – andy@groupresources.com

This electronic transmission and any attached document and/or file is confidential and intended for the use of the individuals to whom it is addressed. This communication may contain material protected by privacy Laws or regulations. Any further distribution or copying of this transmission and/or attached document or file is strictly prohibited. If you received this message in error, please notify the sender and destroy the message and all attached documents and/or files immediately. Group Resources is not liable for any use or misuse contrary to these directions.

For Healthier Employees and Healthier Businesses

8 Costly Mistakes Relating to Specialty Pharmacy

July 31, 2017 § Leave a comment

July 28, 2017                                                              Source: Excelsior Solutions

Recent projections suggest that Specialty Pharmacy costs will account for upwards of 50% of all drug spend in the not too distant future.

Here are eight insights into maximizing the potential within your Specialty Pharmacy strategy:

1. Assuming that your current deal is competitive.

It may be, or it may not be. Here are two considerations:

How long has your current deal been in effect?
The longer it’s been in effect, the more likely it is that the market has “passed it by,” making it less than competitive in the current market.

What are you comparing it to?
Market awareness is enhanced and refined by having good intelligence about multiple deals with multiple vendors in multiple lines of business across the country.

 

2. Assuming that a small improvement in discount wouldn’t be worth the cost to switch vendors.

Because the unit costs in Specialty Pharmacy are so high, even incremental changes in discounts can translate to material financial impact.

For example, if we assume that the average Specialty Pharmacy claim costs $1,000 per month a 1% improvement in discount would translate into $120 in savings per year.

 

3. Assuming that you’re too small to be able to negotiate an aggressive Specialty Pharmacy discount.

The key is to leverage your relationships with negotiating partners who are equipped to make you seem larger than you are by virtue of the other relationships that they bring to the negotiating table.

There truly is strength in numbers.

 

4. Assuming that Specialty Pharmacy is too complex, and you’ll just leave it to the PBM to handle it.

It’s always worth assessing the hidden costs in “bundled” deals.

When a PBM or a carrier owns or has a close relationship with a specialty pharmacy, such bundling can lead to a less aggressive deal than an unbundled relationship with an unaffiliated Specialty Pharmacy provider.

In addition, the mere threat of unbundling a bundled deal may be enough to prompt pricing improvements from a motivated incumbent.

It’s important to survey the marketplace to keep your market intelligence current due to the rapid changes occurring in this high-cost area.

 

5. Assuming that all pharmacies that sell specialty pharmaceuticals are equally able to care for patients that receive specialty pharmaceuticals.

Since Specialty Pharmacy unit costs are so high, it is very important to ensure that each of those very expensive prescriptions is given the best opportunity to succeed in helping patients who need them.

This is best accomplished by wrapping Specialty Pharmacy patients in a suite of high-touch care management services designed to ensure clinical success.

Even though many pharmacies are equipped to sell Specialty Pharmacy prescriptions, not all pharmacies are equipped to deliver the same level of patient support services. Know what to look for to ensure that they do.

While costs are important, they are not the whole story surrounding Specialty Pharmacy.

 

6. Underestimating the financial impact on your plan tomorrow because of minimal financial impact today.

Again, owing to the high unit costs of Specialty Pharmacy claims, Specialty can consume a rapidly growing percentage of your plan’s total drug spend. Today, it is not uncommon for Specialty to exceed 25% of plans overall pharmacy expense.

In one recently examined example in January of 2014, 10% of the lives in a 3,500 life employer group accounted for 33% of that employer’s total pharmacy benefit spending owing to Specialty Pharmacy.

 

7. Failing to realize that up to 50% of spending on Specialty Pharmacy may be hidden inside of your medial benefit.

Because many Specialty Pharmacy items are administered in a physician’s office or hospital setting, they may be properly billed under the medical benefit, as opposed to the pharmacy benefit.

Very often amounts billed for Specialty Pharmacy closely approximate the amount paid for under the pharmacy benefit, resulting in the fact that the costs that are highly visible under the pharmacy benefit may constitute only 50% of the total amount being spent on Specialty Pharmacy.

It’s important to know when it’s best to use the pharmacy benefit, and when its best to use the medical benefit.

 

8. Not managing the site of care based on Specialty Pharmacy contracts.

Because certain sites of care have different reimbursement contracts that may include bundled administration fees, it’s important to optimize the location where Specialty Pharmacy is administered to patients.

Physician offices, hospital outpatient facilities, and other types of locations may influence how much a plan pays for an identical amount of an identical medication within a narrow geographic area.

It’s important to be aware of, and plan for, these differences.

If you have any questions, please do not hesitate to contact me or your Group Resources Account Manager.

 

Andy Willoughby
Senior Vice President & Chief Operating Officer
678 475 3606 – andy@groupresources.com

 

This electronic transmission and any attached document and/or file is confidential and intended for the use of the individuals to whom it is addressed. This communication may contain material protected by privacy Laws or regulations. Any further distribution or copying of this transmission and/or attached document or file is strictly prohibited. If you received this message in error, please notify the sender and destroy the message and all attached documents and/or files immediately. Group Resources is not liable for any use or misuse contrary to these directions.

For Healthier Employees and Healthier Businesses

2018 HSA Inflation Adjusted Amounts

July 21, 2017 § Leave a comment

July 21, 2017

The amount that individuals may contribute annually to their health savings accounts (HSAs) for self-only coverage will rise by $50 next year. For HSAs linked to family coverage, the contribution cap will rise by $150.  These rate changes reflect cost-of-living adjustments, if any, and rounding rules under Internal Revenue Code Section 223.

In Revenue Procedure 2017-37, IRS provides the 2018 inflation-adjusted amounts for Health Savings Accounts.

Annual Contribution Limits

For calendar year 2018, the maximum annual HSA contribution for an eligible individual with self-only coverage is $3,450 (up from $3,400 for 2017).

For calendar year 2018, the maximum annual HSA contribution for an eligible individual with family coverage is $6,900 (up form $6,750 for 2017).

Minimum Deductible Amounts for HSA-Compatible HDHPs

For calendar year 2018, the minimum deductible for HDHPs for self-only coverage is $1,350 (up from $1,300 for 2017) and $2,700 for family coverage (up from $2,600 for 2017).

Out-of-Pocket Limits

For calendar year 2018, the annual out-of-pocket expenses (deductibles, co-payments and other amounts, but not premiums) must not exceed $6,650 for self-only coverage and $13,300 for family coverage.

Account holders who will be 55 or older by the end of year can contribute an additional $1,000 to their HSA.

If you have any questions, please don’t hesitate to contact me or your Group Resources Account Manager.

 

Andy Willoughby
Senior Vice President & Chief Operating Officer
678 475 3606 – andy@groupresources.com

This electronic transmission and any attached document and/or file is confidential and intended for the use of the individuals to whom it is addressed. This communication may contain material protected by privacy Laws or regulations. Any further distribution or copying of this transmission and/or attached document or file is strictly prohibited. If you received this message in error, please notify the sender and destroy the message and all attached documents and/or files immediately. Group Resources is not liable for any use or misuse contrary to these directions.

For Healthier Employees and Healthier Businesses